MyMD Pharmaceuticals Rebrands to TNF Pharmaceuticals; Trading Under New Symbol to Begin Wednesday
MyMD Pharmaceuticals (MYMD) said Monday it has rebranded to TNF Pharmaceuticals to reflect its focus on targeting TNF-alpha for immune and metabolic system regulation.
TNF's stock will begin trading under the new Nasdaq Capital Market symbol "TNFA" before the market opens on Wednesday.
The drugmaker said it plans to advance its clinical development of TNF-alpha inhibitor drug MYMD-1 in sarcopenia, an age-related loss of muscle mass and strength, into mid-stage trials.
Shares of the company were up 1.2% in recent Monday trading.
Price: 1.80, Change: +0.02, Percent Change: +1.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.